Ciprofloxacin was compared with ceftriaxone in a rabbit model of septic arthritis caused by Escherichia coli. Both agents significantly reduced mean E. coli counts in septic joint fluid (P < 0.0005 versus untreated controls) and also within infected synovial tissue (P < 0.01 versus controls). Ciprofloxacin regimens caused a higher frequency (P < 0.05) of synovial tissue sterilization (53%) than did ceftriaxone (25%).
Gram-negative bacillary pyoarthroses remain relatively common in certain patient populations (2, 3, 5) ; the antimicrobial therapy of this disease remains disappointing (5) . We have previously documented the efficacy of a new carboxyquinolone agent, ciprofloxacin, when used in high dosage (80 mg/kg per day) to treat experimentally induced septic arthritis caused by Escherichia coli (4) . The aims of the current study were (i) to delineate the efficacy of ciprofloxacin in experimental E. coli arthritis when lower-dosage regimens were used (10 to 20 mg/kg per day); (ii) to compare the efficacy of ciprofloxacin in this model with that of ceftriaxone, a new 13-lactam agent with excellent bactericidal activity against E. coli (8); (iii) to compare the abilities of these two antibiotics to induce serum and joint fluid bactericidal activity against the infecting E. coli strain; and (iv) to compare and contrast the joint fluid penetration of ceftriaxone with that of ciprofloxacin in this model. The E. coli strain (CSF-76) used to infect animals in this study has been previously described in detail (4) . Stock solutions of ceftriaxone (Hoffman-LaRoche Inc., Nutley, N.J.) and ciprofloxacin (Miles Laboratories, Inc., Elkhart, Ind.) at concentrations of 10 mg/ml were prepared and kept at -70°C until they were thawed on the day of in vitro testing. The MICs and MBCs of ceftriaxone for E. coli CSF-76 in exponential growth phase were determined by using the macrodilution technique (9) with Mueller-Hinton broth. In vitro testing was performed in parallel with inocula of iOs to 107 CFU/ml at pH 6.0 to 7.4 to determine the susceptibility of the infecting E. coli strain at conditions encountered in septic joint fluid in vivo (high bacterial counts and lowered pH [6, 13] MICs and MBCs of ceftriaxone (0.195 and 0.39 ,ug/ml, respectively, at 105-CFU inoculum; pH 7.4) increased notably with an increase in the inoculum to i07 CFU/ml (12.5 and 12.5 ,ug/ml, respectively). All three antibiotic regimens effected a significant lowering of mean joint fluid E. coli counts in treated animals compared with untreated controls (P < 0.0005) ( Table 1) . Also, all three antibiotic regimens caused significant decrements in mean E. coli counts from the same knees sampled pretherapy and on day 4 of therapy (P < Table 2 ). Also, all ceftriaxone trough levels in joint fluid were above the MBC for E. coli CSF-76 as determined at a 105-CFU inoculum (0.39 ,ug/ml); no ciprofloxacin was detectable in joint fluid at trough sampling.
The present study confirmed the excellent in vivo efficacies of both ciprofloxacin and ceftriaxone in experimentally induced E. coli arthritis in terms of: (i) lowering joint fluid and synovial tissue bacterial counts, (ii) sterilizing septic joint fluid, (iii) inducing plasma and joint fluid bactericidal activity, and (iv) penetrating infected joint fluid. Both the current study and the study that previously reported results with this model (4) emphasize the potential role for ciprofloxacin and other carboxy-quinolones in gramnegative pyoarthroses due to susceptible strains. Preliminary clinical experiences in gram-negative skeletal infections in humans have also been encouraging in this regard (R. Greenberg, 1st Int. Ciprofloxacin Workshop, 1985, in press).
